AP300A - Crystalline oxathiolane derivatives. - Google Patents

Crystalline oxathiolane derivatives. Download PDF

Info

Publication number
AP300A
AP300A APAP/P/1992/000395A AP9200395A AP300A AP 300 A AP300 A AP 300A AP 9200395 A AP9200395 A AP 9200395A AP 300 A AP300 A AP 300A
Authority
AP
ARIPO
Prior art keywords
crystalline form
pyrimidin
amino
cis
oxathiolan
Prior art date
Application number
APAP/P/1992/000395A
Other versions
AP9200395A0 (en
Inventor
Paul Ravenscroft
Tony Gordon Roberts
Paul Evans
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10696001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP300(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AP9200395A0 publication Critical patent/AP9200395A0/en
Application granted granted Critical
Publication of AP300A publication Critical patent/AP300A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Secondary Cells (AREA)

Abstract

(-)cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(hl)-pyrimidine-2-one in crystalline form, in particular as needle-shaped or bypyramidyl crystals, pharmaceutical formulations thereof, methods for their preparation and their use in medicine.

Description

CRYSTALLINE OXATHIQLANE DERIVATIVES
The present invention relates to nucleoside analogues and their use in medicine. More specifically the invention is concerned with 1,3-oxathiolane nucleoside analogues, particular physical form thereof, pharmaceutical formulations thereof and the use thereof in the treatment of viral infections.
The compound of formula (I)
also known as BCH-189 or NGPB-21 has been described as having antiviral activity in particular against the human immunodeficiency viruses (HIV’s), the causative agents of AIDS (5th Anti-Aids Conference, Montreal, Canada 5th-9th June 1989: Abstracts T.C.O.l and M.C.P. 63; European Patent Application Publication No. 0382562). The compound of formula (I) is a racemic mixture of the two enantiomers of formulae (1-1) and (1-2):-
and was described and tested in the form of its racemate. The only compound currently approved for the treatment of conditions caused by HIV is 3’-azido-3’deoxythymidine (AZT, zidovudine, BW 509U). However, this compound has a
AV118C '» V r (if1 (j I.'..
P, significant side-effect liability and thus either cannot be employed or, once employed, may have to be withdrawn in a significant number of patients. There is in consequence a continuing need to provide compounds which are effective against HIV but with a concomitant significantly better therapeutic index.
Although the enantiomers of the compound of formula (I) are equipotent against HIV the(-)-enantiomer has considerably lower cytotoxicity than the other enantiomer and is thus the preferred compound as an antiviral agent.
The (-)-enantiomer has the chemical name (-)cis-4-Amino-1-(2hydroxymethyl-l,3-oxathiolan-5-yl)-(lH)- pyrimidin-2-one. It has the absolute stereochemistry of the compound of formula (1-1) which has the name (2R,cis))-4amino-l-(2-hydroxymethyl-l,3-oxathiolan-5-yl)-(lH)-pyrimidin-2-one. The compound is now known as 3TC.
Preferably 3TC will be substantially free of the corresponding (+)-enantiomer, that is to say no more than about 5% w/w of the (+)- enantiomer, preferably no more than about 2%, in particular less than about 1% w/w is present.
International application PCT/GB91/00706, publication no WO91/17159 describes the preparation of 3TC, its antiviral activity and its use in medicine. 3TC is described and prepared in WO91/17159 as a freeze dried powder.
We have now found that 3TC can be obtained in crystalline form and exhibits polymorphism.
There is thus provided in a first aspect of the invention 3TC in crystalline form.
When crystallised from aqueous solution 3TC is obtained in the form of needle-shaped crystals (hereinafter Form I). In this form the crystals are not favoured for pharmaceutical formulation into solid dosage forms because of their physical properties, for example poor flow characteristics. We have further found that under certain conditions 3TC may be obtained in the form of substantially bipyramidyl crystals (hereinafter Form II). The crystal habit of Form II has improved flow characteristics and is thus preferred in the manufacture of solid dosage forms. In addition Form I crystals are a less stable polymorphic forms and certain pharmaceutical unit operations such as milling may cause conversion of
AV118C
AP Ο Ο Ο 3 Ο Ο
-3Form I to Form II, an undesirable characteristic for manufacture of solid dosage forms.
3TC in the form of bipyramidyl crystals has a melting point of greater than about ΙΪΟθΟ, in particular 177-178θΟ when pure. 3TC in the form of needle-like crystals has a melting point of less than about 130®C in particular about 124-127®C in pure form.
3TC in Form II exhibits characteristic absorption bands in its infra red (i.r.) spectrum which are absent from the i.r. spectrum of Form I. In particular Form II exhibits strong absorption bands at -920 and -850 wavenumbers. Further, a characteristic band of Form I at 1110 wavenumbers is absent from the spectrum of Form II.
Form II of 3TC further shows a characteristic endotherm with an onset temperature at 177-178θΟ in its differential scanning calorimetry (DSC) profile. By contrast Form I shows a characteristic endotherm in its DSC profile with an onset temperature at 124-127®C.
There is thus provided in a further aspect of the invention 3TC in the form of needle shaped crystals.
In a further aspect there is provided 3TC in the form of bipyramidal crystals.
In a yet further aspect of the invention there is provided 3TC in crystalline form and having a melting point of greater than 170®C, in particular 177-178θΟ In an alternative aspect there is provided 3TC in crystalline form and having in its DSC profile an endotherm with an onset temperature of 177-178®C.
In a yet further alternative there is provided 3TC in crystalline form and having absorption bands at about 920 and about 850 wavenumbers in its infra red spectrum. In particular there is provided 3TC in which in addition to absorption bands at these wavenumbers a band at 1110 wavenumbers is substantially absent.
3TC may be obtained from its racemate by resolution by any method known in the art for the separation of racemates into their constituent enantiomers, in particular 3TC may be obtained from the known racemate by chiral HPLC, by enzyme mediated enantioselective catabolism with a suitable enzyme such as cytidine deaminase or by selective enzymatic degradation of a suitable derivative
AV118C ^A
- 4 using a 5’-nucleotide. Suitable methods for preparing 3TC are described in WO91/17159.
3TC in the form of needle shaped crystals may be obtained by crystallisation of the compound from aqueous solution or by azeotropic distillation with propan-1ol.
3TC in the form of the preferred bipyramidyl shaped crystals may be obtained by recrystallisation from non-aqueous media, in particular a lower (C2.g) alcohol, for example ethanol, IMS (industrial methylated spirit) or propan-l-ol. In a preferred method 3TC in bipyramidyl form may be obtained from 3TC in needle form by ageing the latter in Industrial Methylated Spirit (IMS) or ethanol at elevated temperature (e.g. 30-70θ, particularly about 50θ(3) for an appropriate time (e.g. 0.53hrs, in particular about 1 hour or more).
Alternatively 3TC in bipyramidyl form may be obtained by heating the compound in needle form above its melting point of 124-127θ, in particular above about 17O®C, for example above about 177-178θϋ and allowing the melt to cool.
In a further alternative 3TC in bipyramidyl form may be obtained by grinding or milling the compound in the form of needle shaped crystals.
Preferably 3TC is in the form of bipyramidyl shaped crystals substantially free of needle crystals. Where these crystals are obtained by recrystallisation or ageing in liquid media the compound will normally be obtained entirely free of needle shaped crystals.
3TC in crystalline form may be used as an antiviral agent as described in WO91/17159 which is incorporated herein by reference.
3TC in crystalline form may be formulated as a pharmaceutical formulation for use as an antiviral agent in described in WO91/17159.
Figure 1 shows 3TC in the form of needle shaped crystals (Form I).
Figure 2 shows 3TC in the form of bipyramidyl shaped crystals (Form II).
Figure 3 is an infra-red spectrum of Form I crystals.
Figure 4 is an infra-red spectrum of Form II crystals.
Figure 5 is a DSC thermogram of Form I crystals.
Figure 6 is a DSC thermogram of Form II crystals.
AP000300
AVI ISC
-5The following examples illustrate the invention but are not intended as a limitation thereof. All temperatures are in ®C.
INTERMEDIATE 1
5-Methoxy-1,3-oxathiolane-2-methanol, benzoate.
A solution of zinc chloride (1.6g) in hot methanol (15ml) was added to a stirred solution of mercaptoacetaldehyde, dimethyl acetal (34.2g) and benzoyloxy acetaldehyde (48.3g) in toluene (1300ml) which was then heated to reflux under nitrogen for 50 min. The cooled mixture was concentrated, diluted with some toluene, then filtered through Kiesulguhr. The combined filtrates and toluene were washed with aqueous saturated sodium bicarbonate solution (x2) and brine, dried (MgSO^) then evaporated to an oil which was subjected to column chromatography on silica (2kg, Merck 9385 ) eluted with chloroform to give the title product as an oil (45.lg) a mixture of anomers (ca 1:1); 1H NMR (DMSO-dg) 3.1-3.3(4H), 3.42(6H), 4.4-4.6 (4H), 5.41 (1H), 5.46 (1H), 5.54 (1H), 5.63 (IH), 7.46 (4H), 7.58 (2H), 8.07 (4H);-ymax (CHBr3)1717.6cm*^.
INTERMEDIATE 2 (±)-cis-l-(2-Benzoyloxymethyl-l,3-oxathiolan-5-yl)-(lH)-pyrimidin-2-4-dione
A mixture of finely ground uracil(9.62g) hexamethyl disilazane (50 ml) and ammonium sulphate (30 mg) was heated at reflux under nitrogen until a clear solution was obtained. This was cooled and then evaporated to a colourless oil, which was dissolved, under nitrogen atmosphere, in acetonitrile (100ml). The solution was added to a stirred ice cooled solution of 5-methoxy-l,3-oxathiolane-2methanol, benzoate (intermediate 1) (19.43g), in acetonitrile (600ml) and trimethyl silyl trifluoromethanesulphonate (14.7ml) was added. The ice bath was removed, and the solution was heated at reflux under nitrogen for 45 mins. After cooling and evaporation, the residue was purified by column chromatography over 1kg of silica gel (Merck 9385) eluting with chloroform/methanol 9:1. Appropriate fractions were cooled and evaporated to afford a crude residue. This was fractionally crystallized from the minimum of hot methanol (c.l200ml) to afford the title compound (6.32g)
AV118C 1
-6as white crystals. IH NMR( d^DMSO) δ 11.36 (lH,bs). 7.50-8.00 (6H,m), 6.20 (lH,t), 5.46 (2H,m), 4,62 (2H, m), 3.48 (IH, m), 3.25 (IH, m).
INTERMEDIATE 3 (t )-(cis)-4-Amino-l-(2-benzoy loxy methyl-1,3-oxathiolan-5-yl)-( 1H)pyrimidin-2-one
Method (a)
A suspension of cytosine (20.705g) and ammonium sulphate (few mgs) in hexamethyldisilazane (110ml) was stirred and heated at reflux for 2’/2h, under nitrogen. Solvent was removed by evaporation, and the residual solid was dissolved in dry acetonitrile (350ml). This solution was transferred using flexible needle techniques into a stirred, ice-chilled solution of 5-methoxy-l,3-oxathiolane-2methanol, benzoate (Intermediate I) (43.57g) in acetonitrile (650ml) under nitrogen. Trimethy lsi lyl trifluoromethanesulphonate (33ml) was added, the solution was allowed to warm to ambient temperature (1 x/zh) then heated to reflux for an overnight period. The residue mixture was concentrated, diluted with saturated aqueous sodium bicarbonate solution (500ml), then extracted with ethyl acetate (3x500ml). The combined extracts were washed with water (2x250ml) and brine (250ml) dried (MgSO^) then evaporated to a foam which was subjected to column chromatography on silica (600g, merck 7734), eluted with ethyl acetate-methanol mixtures to give a mixture of anomers (ca 1:1 31.59g). The mixture was crystallised from water (45ml) and ethanol (9.0ml) to give a solid (10.23g) which was recrystallised from ethanol (120ml) and water (30ml) to give the title product as a white solid (9.26g);Xmax (MeOH) 229.4mm (E1% 610); 272.4mm (E1% lcm 1cm
293); ]H NMR (DMSO d6) δ 3.14 (IH), 3.50 (IH), 4.07 (2H), 5.52 (IH), 5.66 (IH), 6.28 (IH), 7.22 (2H), 7.56 (2H), 7.72 (2H), 8.10 (2H).
Method (b)
AP Ο Ο Ο 3 Ο Ο
AV118C
- 7Phosphorus oxychloride (7.0ml) was added dropwise to a stirred , ice-cooled suspension of 1,2,4-triazole (11.65g) in acetonitrile (120ml) then, keeping the internal temperature below 15θΟ, triethylamine (22.7ml) was added dropwise. After 10 min a solution of (+)-cis -l-(2-benzoyloxymethyl-l,3-oxathiolan-5-yl)-(lH)pyrimidin-2,4-dione (Intermediate 2) (6.27g) in acetonitrile (330ml)was slowly added. Stirring was then continued at room temperature overnight. The mixture was cooled by means of an ice bath and triethylamine (30ml) was slowly added followed by water (21ml). The resultant solution was evaporated, and the residue was partitioned between saturated sodium bicarbonate solution (400ml) and chloroform (3x200ml). The combined chloroform extracts were dried and magnesium sulphate, filtered and evaporated to give a crude residue (9.7g). The residue was dissolved in 1,4-dioxan (240ml) and concentrated aqueous ammonia solution (s.g 0.880, 50ml) was added. After l*/2h the solution was evaporated and the residue dissolved in methanol. This caused precipitation of a solid, which was filtered off. The mother liquors were purified by column chromatography over silica gel (Merck 9385, 600g). Appropriate fractions were pooled and evaporated to give the title compound as a fawn solid (2.18g), identical to that obtained by Method (a).
INTERMEDIATE 4 ( *)-(cis)-4-Amino-l-(2-hvdroxvmethyl-l,3-oxathiolan-5-vl)-(lH)pyrimidin-2-one
A suspension of (cis)-4-amino-l-(2-benzoyloxymethyl-l,3-oxathiolan-5-yl)(lH)-pyrimidin-2-one (Intermediate 3) (8.19g) and Amberlite IRA-400 (OH) resin (8.24g) in methanol (250ml) was stirred and heated to reflux for 1 ‘Ah. Solids were removed by filtration then washed with methanol. The combined filtrates were evaporated. The residue was triturated with ethyl acetate (80ml). The resulting white solid was collected by filtration to give the title product (5.09g), IH NMR (DMSO-dg) 3.04 (IH), 3.40 (IH), 3.73 (2H), 5.18 (IH), 5.29 (IH), 5.73 (IH), 6.21 (IH), 7.19 (2H), 7,81 (IH).
INTERMEDIATE 5
AV118C 1 ; '>
-8(-)-cis-4-Amino-l-(2-hydroxymethyl-l,3-oxathiolan-5-yl)-(lH) pyrimidin-2-one (i) Three 50ml flasks of nutrient broth (Oxoid Ltd) were inoculated with a loopful each of Escherichia coli (ATCC 23848) scraped from a Nutrient Agar plate. The flasks were incubated overnight at 37^C with shaking at 250 rev/min and then each flask was used to inoculate 41 of CDD medium (glutamic acid, 3g/l; MgSO4, 0.2g/l: K2SO4, 2.5g/l; NaCl, 2.3g/l, Na2HPO42H20, l.lg/1, NaH2PO42H20 0.6g/l cytidine, 1.2g/l) in a seven litre fermenter. The cultures were fermented at 750 rev/min, 37^C with aeration at 41/min. After growth for 24hrs the cells were collected by centrifugation (5000g, 30 minutes) to yield 72g wet weight. The cell pellet was resuspended in 300ml of 20mM Tris HC1 buffer (pH 7.5) and disrupted by sonication (4 x 45 seconds). The cell debris was removed by centrifugation (30,000 g, 30 minutes) and the protein in the supernatant was precipitated by addition of ammonium sulphate to 75% saturation. The precipitate was collected by centrifugation (30,000g. 30 minutes) and the pellet was resuspended in 25ml of HEPES buffer (lOOmM, pH 7.0) containing ammonium sulphate (75% saturation). Enzyme solution was prepared by centrifugation at 12,000 rpm for 30 mins. The supernatant was discarded and the pellet dissolved in Tris HC1 buffer (pH 7.0; lOOm.M) to the original volume.
(ii) Intermediate 4 (115mg was dissolved in water (100ml), and stirred. Enzyme solution (0.5ml) was added, and the mixture was maintained at a constant pH by the continual addition of HC1 (25mM). The conversion was monitored by chiral HPLC, which showed that the (+) enantiomer of the substrate was preferentially deaminated. After 22hr the (+) enantiomer of the substrate (RT 12.5min) had been completely removed, and the solution was adjusted to pH 10.5 by the addition of cone, sodium hydroxide.
The solution produced above was eluted through a column of QAE Sephadex (A25; Pharmacia; 30X 1.6cm), pre-equilibrated to pHl 1. The column was washed
AP Ο 0 Ο 3 0 Ο
AV118C
-9analysed by reversed phase HPLC. Fractions 5-13, containing the unreacted (-) enantiomer of the substrate, were combined and adjusted to pH 7.5 with HCI. Fraction 47, containing deaminated product, was adjusted to pH7.5 with dil. NaOH. Analysis by chiral HPLC showed that this material was a mixture, consisting of one enantiomer (RT 10.2min) as the major component with the other enantiomer (RT 8.5min) as a minor component (e.e ca 90%).
(iii) Stage (ii) above was repeated on a larger scale . The compound of Example 1 (363mg) in 250ml of water was incubated with enzyme solution (0.5ml), prepared as in Stage (i). Further aliquots (0.5ml) of enzyme were added after 18 and 47 hrs. The reaction mixture was stirred for 70hr., then left standing for a further 64hr. Analysis by chiral hplc indicated that the (+) enantiomer of the substrate had been completely deaminated, and the resulting solution was adjusted to pH10.5 with NaOH.
The solution above was loaded onto the same QAE column, and eluted as in stage (i). Fractions 2-6, containing a mixture of the residual substrate and deaminated product, were bulked. Fractions 7-13, containing the residual substrate ((-) enantiomer), were bulked and adjusted to pH7.5. Fractions 25-26, containing deaminated product, were bulked and neutralised
Fractions 2-6 above were re-eluted through the same QAE column. Fractions
3-11 from this second column contained unrected substrate ((-) enantiomer). Fraction 70 contained the deaminated product.
(iv) The resolved substrate fractions from stage (ii) and (iii) were combined and adjusted to pH7.5. This solution was eluted through a column of XAD-16 (40x2.4cm), packed in water. The column was washed with water, and then eluted with acetone: water (1:4 v/v). Fractions containing the desired (-) enantiomer were bulked and freeze-dried to give a white powder (190mg).
The HPLC methods used above were as follows:1. Reversed Phase analytical HPLC
AV118C
HA
- 10Column
Eluant
Flow
Detection
Retention Times : Capital Cartridge
Spherisorb ODS-2 (5uM)
150x4.6mm : Ammonium dihydrogen phosphate (50mM)+
5% MeCN : 1.5ml/min : UV, 270nm : BCH 189 5.5min deaminated BCH-189 8.1min
2. Chiral analytical HPLC
Column : Cyclobond I Acetyl
250x4.6mm
Eluant : 0.2% Triethylammonium acetate (pH7.2)
Flow : l.Oml/min
Detection : UV, 270nm
Retention Times BCH 189 11.0 and 12.5min : deaminated BCH-189 8.5 and 10.2 min (The bioconversion was followed by monitoring the loss of the peak at 12.5min., and accumulated of product at 10.2min).
Example 1
A suspension of Intermediate 5 (64.8g) in water (200mL) was heated to 45θ to give a solution. The solution was cooled to 30θ.
The product crystallised as an unstirrable mass. This was broken up and the suspension stirred at ca. 10° for lh.
The product was isolated by filtration and washed with ethanol (IMS; 2 x 30mL) then dried in vacuo at 45θ for 24h to give 3TC as Form I (fine needle crystals).
AP Ο Ο Ο 3 Ο Ο
AV118C
- 11 The compound had an i.r. spectrum and DSC thermograph identical to Figures and 5 respectively.
Example 2
A suspension of the compound of Example 1 (lO.Og) in industrial methylated spirits (IMS; 200mL; 20 volumes) was heated to reflux to give a clear solution. The solution was filtered hot and the filtrate was distilled at atmospheric pressure until lOOmL (10 volumes) of solution remained. The solution was seeded with authentic material^ and allowed to cool from 80θ to 25θ over lh. Crystallisation began at 79°. The suspension was stirred at 15θ for lh. The product was isolated by filtration and washed with IMS (lOmL; 1 volume). Drying in vacuo at 50θ gave the title compound as aggregates of bipyramides (8.42g) m.p. 179-181θ. (-)-cis-4amino-l-(2-hydroxymethyl-l,3-oxathiolan-5-yl)-(lH)-pyrimidin-2-one.
Assay Found : C,41.9; H.4.85; N.18.35 C8H11N3°3S requ>res : C,41.9; H,4.8; N,18.3%
The compound had an i.r. spectrum and DSC thermograph identical to Figures and 6 respectively.
Example 3
A suspension of the product of Example 1 (20.Og) in Industrial Methylated Spirits (IMS; lOOmL; 5 volumes) was stirred slowly at 50θ for lh.
A small sample (ca lOOmg) was removed, dried in vacuo at 50θ and examined by microscopy and differential scanning calorimetry (DSC).
The sample was 100% Form II (bipyramidal habit).
The suspension was stirred at 50θ for a further 2h and a sample removed. Microscopy showed no change.
The suspension was stirred at 50θ for 22h, then cooled to 20θ and stirred for lh.
The suspension was filtered, the product washed with IMS (20mL; lvol) and dried in vacuo to give as a white crystalline solid (17.13g) (-)-cis-4-amino-1-(2hydroxymethyl-l,3-oxathiolan-5-yl)-(lH)-pyramidin-2-one m.p. 180-181θ.
<1 C.
AV118C
- 12Assay Found : C,41.85; H,4.85; N,18.3 C8H11N3°3S Requires : C.41.9; H,4.8; N.18.3%
The product had an i.r. spectrum and DSC thermogram identical to those of Figures 4 and 6 respectively.
Example 4
X-Ray Crystallography data for Form 11
Crystal Data :
C8H11N3°3SM = 229·26·
Tetragonal, a = b = 8.749(3), c = 26.523(9)A, V= 2030(2)A3 (by least-squares refinement on diffractometer angles for 14 automatically centred reflections, 1 = 1.54184A).
Space group P4^2j2 (No. 96), z = 8, Dc = 1.50g cm'3.
F(000) = 960, m(Cu-Ka) = 27.5 cm'1.
Dimensions of data crystal 0.48 x 0.32 x 0.30 mm.
Single crystals of Form II (colourless bipyramids) were examined by X-ray diffraction. A total of 1651 reflections were measured (3 < 2J < 115θ) on a Siemens R3m/V diffractometer with monochromatised Cu-Ka radiation and using 2J/w scans. The structure was solved by direct methods and the non-hydrogen atoms refined anisotropically. The hydrogen atoms attached to carbon were idealised (C-H = 0.96A) and allowed to ride on their parent carbon atoms. Three Hs on -NH2 and -OH groups were located from a difference Fourier map. All H atoms w-ere refined isotropically. Refinement converged to give R = 0.068, Rw = 0.069, w'^ = (s3(F) + 0.005[F]2], Maximum residual electron density was 0.45 eA'3. The absolute
AP Ο Ο Ο 3 Ο Ο
AV118C
- 13Example 5
Pharmaceutical Formulations (a) lOOmg Tablets
Ingredients per tablet
3TC (Form II) lOO.Omg
Microcrystalline Cellulose NF 189.5mg
Sodium Starch Glycolate NF 9.0mg
Magnesium Stearate NF 1.5mg
Total Weight 300.0mg
The 3TC (Form II), microcrystalline cellulose and sodium starch glycolate
were sieved and blended in a V-blender for about 15 minutes. Sieved magnesium stearate was then added and blending continued for a further 2 minutes.
The blend was compressed in standard tabletting equipment and then film coated with an aqueous suspension of grey Opadry to produce aesthetically acceptable tablets.
(b) 300m g Tablets
Ingredients per tablet
3TC (Form II) 300.0mg
Microcrystalline Cellulose NF 279.Omg
Sodium Starch Glyco,ate NF 18.0mg
Magnesium Stearate NF 1.5mg
Total Weight 600.0mg

Claims (25)

1· (-)cis- t-Amino-l-(2-hydrox> mcthyl-1,3-oxatliiolan-5 ' (IH)-pyrimidin-2one in crystalline form.
2. (-)-cis-4-Amino-l-(2-hydroxymetbyl-l,3-oxathiolan-5-?! -ilH)-pyrimidin-2one in the form of bipyramidyl crystals.
3. The crystalline form as claimed in claim 1 or claim 2 having a melting point of greater than 170°C.
4. The crystalline form as claimed in any one of claims 1 io 3, having a melting point of 177-178°C.
5. The crystalline form as claimed in any one of claims 1 to 4 having absorption bands in its infra-red spectrum of 920 and 850wave numbers.
6. The crystalline form as claimed in any one of claims 1 to 5 having no absorption band in its infra-red spectrum at 1110 wave numbers.
7. The crystalline form as claimed in any one of claims 1 to 6 having an endotherm with an onset temperature at 177-178°C in its differential scanning calorimetry profile.
8. (-)cis-4-Amino-l-(2-hydroxymethyl-l,3-oxathiolan-5y!)-(IH)-pyrimidin-2one in the form of needle shaped crystals.
9. The crystalline form as claimed in claim 1 or claim 8 ha'. ing a melting point of less than about 130°C.
10. The crystalline form as claimed in claim 1, claim 8 cr claim 9 having a melting point of 124-127°C.
11. The crystalline form as claimed in claim 1, or any one of claims 8-11 having an endotherm with an onset temperature of 124-127°C in its differential scanning calorimetry profile.
12. The crystalline form as claimed in claim 1 or any one of claims 8 to 11 having an absorption band in its infra-red spectrum at about 1110 wave numbers.
13. (-)cis-4-Amino-l-(2-hydrcxymethyl-l,3-oxathiolan-5-yU-(IH)-pyrimidin-2one in the crystalline form as shown in Figure 1.
14. (-)cis-4-Amino-l-(2ihydroxymethyl-l,3-oxathiolan-5-yl)-(IH)-pyrimidin-2one in the crystalline form as shown in Figure 2.
AP Ο Ο Ο 3 Ο Ο
AV118C
- 14•-4 ’ V. tha: v\
- 15 15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
(-)cis-4-Amino-l-(2-hydroxy methy l-l,3-oxathiolan-5-yl)-(IH)-pyrimidin-2one in crystalline form and having an infra-red spectrum as shown in Figure 3. (-)cis-4-Amino-l-(2-hydroxymethyI-l,3-oxathiolan-5-yl)-(IH)-pyrimidin-2one in crystalline form and having an infra-red spectrum as shown in Figure 4. A method for the preparation of (-)-cis-4-Amino-l-(2-hydroxymethyl-l,3oxathiolan-5-yl)-(IH)-pyrimidin-2-one in crystalline form which comprises crystallisation of the compound from aqueous solution.
A method for the preparation of (-)-cjs-4-Amino-l-(2-hydroxymethyl-l,3oxathiolan-5-yl)-(lH)-pyrimidin-2-one in crystalline form which comprises areotropic distillation of an aqueous solution of the compound with propan-1ol.
A method for the preparation of (-)-cis-4-Amino-l-(2-hydroxymethyl-l,3oxathiolan-5-yl)-(IH)-pyrimidin-2-one in crystalline form which comprises recrystallisation from non-aqueous medium.
A method as claimed in claim 19 wherein the non-aqueous medium is a C2.g alcohol.
A method as claimed in either claim 20 or claim 21 wherein the non-aqueous medium is selected from ethanol and industrial methylated spirit.
A method for the preparation of (-)-cis-4-Amino-l-(2-hvdroxymethyl-1.3oxathiolan-5-yl)-(IH)-pyrimidin-2-one in the form of bypyramidyl crystals which comprises aging the compound in the form of needle shaped crystals in ethanol or industrial methylated spirits at elevated temperature.
A pharmaceutical formulation comprising (-)-cis-4-amino -1-(2hydroxymethyl-l,3-oxathiolan-5-yl)-(IH)-pyrimidin-2-one in crystalline form and a pharmaceutically acceptable carrier therefor.
A pharmaceutical formulation as claimed in claim 23 in a form suitable for oral administration.
A pharmaceutical formulation as claimed in claim 23 or claim 24 in the form of a tablet or capsule.
APAP/P/1992/000395A 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives. AP300A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919111902A GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds

Publications (2)

Publication Number Publication Date
AP9200395A0 AP9200395A0 (en) 1992-07-31
AP300A true AP300A (en) 1994-01-20

Family

ID=10696001

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1992/000395A AP300A (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives.

Country Status (31)

Country Link
US (1) US5905082A (en)
EP (2) EP1099700A1 (en)
JP (1) JP2851480B2 (en)
KR (1) KR100244008B1 (en)
AP (1) AP300A (en)
AT (1) ATE212630T1 (en)
AU (2) AU656379B2 (en)
BG (1) BG60914B1 (en)
CA (2) CA2070230C (en)
CZ (1) CZ284513B6 (en)
DE (1) DE69232387T2 (en)
DK (1) DK0517145T3 (en)
ES (1) ES2171158T3 (en)
GB (1) GB9111902D0 (en)
GE (1) GEP19991834B (en)
HK (1) HK1009599A1 (en)
IE (2) IE921780A1 (en)
IL (1) IL102073A (en)
IS (2) IS1867B (en)
MX (1) MX9202619A (en)
NO (1) NO301713B1 (en)
NZ (1) NZ242981A (en)
OA (1) OA09913A (en)
PT (1) PT517145E (en)
RU (1) RU2102393C1 (en)
SG (1) SG52455A1 (en)
SK (1) SK281249B6 (en)
TW (1) TW254939B (en)
UA (1) UA41265C2 (en)
WO (1) WO1992021676A1 (en)
ZA (1) ZA924007B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581979A (en) * 1983-07-01 1986-04-15 Automotive Products Plc Shipping and installation restraining clip for master cylinder input member
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
NZ333099A (en) 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2690137C (en) * 2001-03-01 2012-11-13 Gilead Sciences, Inc. Polymorphic and other crystalline forms of cis-ftc
US6600044B2 (en) 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
WO2003027106A1 (en) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Process for the preparation of crystalline polymorph ii of lamivudine
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
CA2505130C (en) * 2002-11-08 2009-10-06 Glaxo Group Limited Pharmaceutical compositions
ATE398455T1 (en) 2003-01-14 2008-07-15 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR ANTIVIRAL COMBINATION THERAPY
ATE415421T1 (en) * 2004-11-10 2008-12-15 Novartis Vaccines & Diagnostic DEAMIDATED INTERFERON BETA
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
JP5184511B2 (en) * 2006-04-18 2013-04-17 ルピン・リミテッド A new crystalline form of lamivudine
AR068374A1 (en) * 2007-09-06 2009-11-11 Combino Pharm Sl NEW PHARMACEUTICAL COMPOSITIONS OF THE LAMIVUDINA BETA COMPLEX - CICLODEXTRINA
US20100190982A1 (en) * 2007-09-17 2010-07-29 Janardhana Rao Vascuri Process for the preparation of lamivudine form i
WO2009069011A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
AU2008331167A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine
WO2009069013A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Crystalline form i of lamivudine and its preparation
WO2009127996A1 (en) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Novel crystalline form of lamivudine
EP2318398A4 (en) * 2008-09-01 2011-12-07 Hetero Research Foundation Process for preparing lamivudine polymorph form
EP2350065A1 (en) * 2008-11-12 2011-08-03 Lupin Ltd. A novel polymorph of emtricitabine and a process for preparing of the same
CN101531656B (en) * 2009-03-24 2010-12-08 福建广生堂药业有限公司 Lamivudine crystal form and preparation method thereof
CN101993439B (en) * 2009-03-24 2013-04-24 福建广生堂药业股份有限公司 Lamivudine crystal form and preparation method thereof
EP2435052B1 (en) * 2009-05-27 2015-07-15 Hetero Research Foundation Solid oral dosage forms of lamivudine with isomalt
US8710218B2 (en) 2009-07-15 2014-04-29 Lupin Limited Process for preparation of Efavirenz
WO2011045815A2 (en) 2009-10-14 2011-04-21 Matrix Laboratories Ltd. Process for the preparation of lamivudine and novel salts in the manufacture thereof
KR20170078868A (en) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 Antibiral therapy
US20120295930A1 (en) * 2010-02-03 2012-11-22 Shankar Rama Novel process for the preparation of cis-nucleoside derivative
CA2789078A1 (en) * 2010-02-12 2011-08-18 Merck Sharp & Dohme Corp. Preparation of lamivudine form i
US20130115237A1 (en) 2010-06-09 2013-05-09 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
WO2013021290A1 (en) 2011-08-05 2013-02-14 Lupin Limited A stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CN114099454B (en) * 2020-08-31 2023-06-27 长春海悦药业股份有限公司 Lamivudine tablet and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NONE *

Also Published As

Publication number Publication date
GB9111902D0 (en) 1991-07-24
US5905082A (en) 1999-05-18
DK0517145T3 (en) 2002-05-06
SG52455A1 (en) 1998-09-28
EP1099700A1 (en) 2001-05-16
SK125793A3 (en) 1994-11-09
NO301713B1 (en) 1997-12-01
SK281249B6 (en) 2001-01-18
DE69232387T2 (en) 2002-09-26
AP9200395A0 (en) 1992-07-31
ATE212630T1 (en) 2002-02-15
PT517145E (en) 2002-07-31
MX9202619A (en) 1992-12-01
DE69232387D1 (en) 2002-03-14
NO922182D0 (en) 1992-06-02
AU656379B2 (en) 1995-02-02
JPH06211848A (en) 1994-08-02
BG60914B1 (en) 1996-06-28
OA09913A (en) 1994-09-15
BG98254A (en) 1994-07-29
RU2102393C1 (en) 1998-01-20
ZA924007B (en) 1993-04-28
AU1881092A (en) 1993-01-08
CA2070230A1 (en) 1992-12-04
IE20020782A1 (en) 2003-04-02
CZ284513B6 (en) 1998-12-16
AU1736192A (en) 1993-03-11
GEP19991834B (en) 1999-11-05
IE921780A1 (en) 1992-12-16
CA2311988A1 (en) 1992-12-04
CA2311988C (en) 2005-11-15
KR100244008B1 (en) 2000-03-02
EP0517145A1 (en) 1992-12-09
JP2851480B2 (en) 1999-01-27
CZ261293A3 (en) 1994-04-13
IL102073A0 (en) 1993-01-14
IL102073A (en) 1996-05-14
ES2171158T3 (en) 2002-09-01
IS3873A (en) 1992-12-04
NO922182L (en) 1992-12-04
IS1867B (en) 2003-05-02
IS4268A (en) 1995-02-27
EP0517145B1 (en) 2002-01-30
TW254939B (en) 1995-08-21
HK1009599A1 (en) 1999-06-04
NZ242981A (en) 1994-04-27
CA2070230C (en) 2004-08-03
WO1992021676A1 (en) 1992-12-10
KR930000511A (en) 1993-01-15
UA41265C2 (en) 2001-09-17

Similar Documents

Publication Publication Date Title
AP300A (en) Crystalline oxathiolane derivatives.
IE83503B1 (en) Crystalline oxathiolane derivatives
JP2927546B2 (en) 1,3-oxathiolane nucleoside analogues
JP2015028045A (en) Polymorphic and other crystalline form of cis-ftc
JP6980779B2 (en) Nucleoside cyclic phosphate compounds and their use, which are antiviral prodrugs based on liver delivery
TWI749281B (en) Liver delivery of entecavir prodrug nucleoside cyclic phosphate compound and application
EP2225232A1 (en) Process for the preparation of substituted 1,3-oxathiolanes
EP0456514B1 (en) 2-Fluoroneplanocin A and its production